Tags: Drug.
BAY 73-6691 is a drug developed by Bayer for the treatment of Alzheimer’s disease. It was the first compound developed that acts as a phosphodiesterase inhibitor selective for the PDE9A subtype. The PDE9A enzyme is expressed primarily in the brain with high concentrations in the cerebellum neocortex striatum and hippocampus and acts to limit the cGMP-mediated signal transduction which occurs following glutamate binding to NMDA receptors.
